Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial save search
AFRM IMPORTANT DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Affirm Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 6 Deadline in Securities Class Action - AFRM
Published: 2023-02-04 (Crawled : 00:20) - prnewswire.com
FXLV | News | $3.16 1.61% 0.0% 480K
|
Arts, Entertainment, and Recrea...
| Email alert
Add to watchlist
AFRM | News M | $18.14 -14.19% -16.54% 29M
|
| Email alert
Add to watchlist
trial deadline
FXLV IMPORTANT DEADLINE MONDAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages F45 Training Holdings Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 6 Deadline in Securities Class Action - FXLV
Published: 2023-02-04 (Crawled : 20:20) - prnewswire.com
FXLV | News | $3.16 1.61% 0.0% 480K
|
Arts, Entertainment, and Recrea...
| Email alert
Add to watchlist
BLRX | News | $0.62 1.39% 1.37% 320K
|
Health Technology
| Email alert
Add to watchlist
trial deadline
Sanofi Admits Defeat for Myasthenia Gravis Candidate, Drops Phase III Trial
Published: 2023-02-03 (Crawled : 16:00) - biospace.com/
SNY | News | $46.02 -2.58% -2.65% 3.5M
|
Health Technology
|
| O: -4.01%
H: 0.0%
C: 0.0%
for trial sanofi
Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
Published: 2023-02-03 (Crawled : 14:20) - prnewswire.com
BPMC | $45.64 -6.97% -7.49% 810K
|
Health Technology
|
| O: 5.37%
H: 0.0%
C: 0.0%
ayvakit meeting trial positive
Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)
Published: 2023-02-02 (Crawled : 22:00) - globenewswire.com
UTHR M | $252.81 -2.57% -2.64% 500K
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
patent trial therapeutics
Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion
Published: 2023-02-02 (Crawled : 16:00) - biospace.com/
SKYE | $0.0503 0
|
Transportation and Warehousing
| Email alert
Add to watchlist
sbi-100 pharma services for trial bioscience
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossExpects to Commence Phase 2a of CAReS During the First Quarter of 2023
Published: 2023-02-02 (Crawled : 15:20) - biospace.com/
AZN | $63.45 0.48% 0.47% 4.8M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
ARTL A | $3.06 -0.65% -0.65% 36K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
art27 treatment cares for trial art27.13
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Published: 2023-02-02 (Crawled : 15:00) - biospace.com/
AMLX | $36.6 -1.08% -1.09% 650K
|
|
| O: -0.2%
H: 3.98%
C: -5.88%
amx0035 pharmaceuticals global als trial
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2023-02-02 (Crawled : 14:20) - globenewswire.com
AZN | $63.45 0.48% 0.47% 4.8M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
ARTL A | $3.06 -0.65% -0.65% 36K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
art27 treatment cares for trial art27.13
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Published: 2023-02-02 (Crawled : 14:00) - biospace.com/
AVXL | $11.27 -0.88% -0.89% 1.1M
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
anavex anavex®2-73 trial rett syndrome
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
Published: 2023-02-02 (Crawled : 13:20) - globenewswire.com
MLTX | $12.08 0.25% 0.25% 85K
|
|
| O: 2.51%
H: 1.71%
C: -1.63%
SNY | News | $46.02 -2.58% -2.65% 3.5M
|
Health Technology
|
| O: -1.44%
H: 0.0%
C: 0.0%
nanobody trial
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic FibrosisPatient dosing expected to begin in mid-February with topline data anticipated by mid-2023
Published: 2023-02-02 (Crawled : 13:00) - biospace.com/
FWBI | $5.14 -5.34% -5.64% 270K
|
Manufacturing
|
| O: -3.21%
H: 25.54%
C: 5.85%
biopharma for topline expected trial
NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior
Published: 2023-02-02 (Crawled : 12:00) - prnewswire.com
NRXP | $1.255 0.4% 0.4% 130K
|
Manufacturing
|
| O: -0.85%
H: 6.84%
C: 6.84%
nrx-101 pharmaceuticals for trial depression
NBEV DEADLINE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages NewAge Inc. Investors to Secure Counsel Before Important February 6 Deadline in Securities Class Action Initiated by the Firm - NBEV, NBEVQ
Published: 2023-02-02 (Crawled : 01:00) - prnewswire.com
TTCF | $1.65 -4.07% -4.24% 1.4M
|
Consumer Non-Durables
|
| O: 9.15%
H: 10.18%
C: 2.99%
SPPI S | $0.829 2.88% 2.8% 2M
|
Health Technology
|
| O: 28.17%
H: 1.1%
C: -11.45%
trial trusted deadline initiated
Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer
Published: 2023-02-01 (Crawled : 15:00) - biospace.com/
MRSN | $7.025 1.96% 1.92% 1.3M
|
Health Technology
|
| O: 0.15%
H: 3.03%
C: 1.97%
expansion trial therapeutics cancer
GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
Published: 2023-02-01 (Crawled : 14:00) - biospace.com/
GRNA | $1.135 1.34% 1.32% 220K
|
Professional, Scientific, and T...
|
| O: 9.76%
H: 0.0%
C: -5.87%
covid-19 candidate vaccine mrna trial approval
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Tattooed Chef, Inc. Investors to Secure Counsel Before Important Deadline in First Filed Securities Class Action Commenced by the Firm - TTCF
Published: 2023-02-01 (Crawled : 04:00) - prnewswire.com
TTCF | $1.65 -4.07% -4.24% 1.4M
|
Consumer Non-Durables
|
| O: -1.29%
H: 0.0%
C: 0.0%
DAKT | $4.12 -0.48% -0.49% 260K
|
Electronic Technology
|
| O: 1.47%
H: 2.77%
C: 0.96%
trial deadline
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
Published: 2023-01-31 (Crawled : 17:00) - biospace.com/
ATRC | $47.23 0.02% 0.02% 190K
|
Health Technology
| Email alert
Add to watchlist
trial
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
Published: 2023-01-31 (Crawled : 14:00) - biospace.com/
ARCT | $21.97 -4.1% -4.28% 370K
|
Health Technology
|
| O: -0.64%
H: 4.14%
C: 4.14%
arct-032 fibrosis for application trial approval therapeutics
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
Published: 2023-01-31 (Crawled : 13:00) - biospace.com/
FWBI | $5.14 -5.34% -5.64% 270K
|
Manufacturing
|
| O: -0.9%
H: 4.88%
C: -1.99%
biopharma fibrosis trial pancreatic
Gainers vs Losers
| 63% | 37% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.